Skip to main content

Alzheimer's disease

Knowing a risk for Alzheimer’s disease gives you the power to take action

Previously, hearing the words “Alzheimer’s disease” may have caused worry and a sense of being powerless. Did you know a simple blood test from Quest can measure amyloid ratio? This ratio measures levels of 2 biomarkers, where certain ratio results may suggest a risk of developing Alzheimer’s disease. This can potentially guide important conversations with your doctor to help monitor any changes in your health so you can take action.

What is Alzheimer’s disease?

Alzheimer’s disease is the most common cause of dementia, accounting for an estimated 60% to 80% of cases.1 The disease can slowly destroy memory and thinking skills and, eventually, the ability to carry out the simplest tasks. People with Alzheimer’s also experience changes in behavior and personality.

How is Alzheimer’s disease diagnosed?

If you’re 65 years or oldera and notice some issues with your memory or finding the correct word, it’s important to recognize that not all people with memory issues have Alzheimer’s. Other causes may include normal aging, certain medications, mild cognitive impairment (ie, memory and thinking difficulties beyond normal aging but not significant enough to impact activities of daily living), or other medical conditions.

Doctors use several methods and tools to help determine if a person with thinking or memory problems has Alzheimer’s or another form of dementia. These include memory tests, psychiatric evaluation, brain scans, and other standard medical tests to rule out other causes.

A screening test from Quest may be right for you if you have 1 or more of the following risk factors associated with Alzheimer’s disease:

Assessing a risk for Alzheimer’s disease can start with a blood test

There are many risk factors for Alzheimer’s disease. With a simple blood test from Quest, you and your doctor can understand if you are at risk for 1 of them, so you can take action.

Quest offers a reliable, noninvasive screening test that measures amyloid ratio, which is 1 factor in determining risk of Alzheimer’s disease. This ratio is based on 2 biomarkers that have been reported as helping to detect early signs associated with the risk of developing Alzheimer’s disease.

FEATURED TEST

AD-Detect™ Test for Alzheimer’s Disease Risk

This blood screening test from Quest measures A-beta 42, A-beta 40, and provides the A-beta 42/40 ratio blood levels.

It can help you and your doctor establish a baseline and, if used as part of an annual screen, assess change over time.
40987-infographic-3-paddedmore-v2.png

Knowing a potential risk for Alzheimer’s disease gives you the power

Treatments are emerging to lessen the impact of dementia and Alzheimer’s disease, and there is growing evidence that healthy lifestyle choices may also reduce risk.2

  • Tobacco prevention and control
  • Blood pressure control
  • Cardiovascular health management
  • Diabetes prevention and management
  • Obesity prevention and control

Today, you have the power to take action

Your blood screening test can provide important information to help you and your doctor make informed decisions about your health.

  • Make important lifestyle changes
  • Identify if you’re a candidate for early antibody treatment, which can help slow disease progression3
  • Monitor changes in your health over time

AD-Detect Test for Alzheimer’s Disease Risk is covered by most health plans and Medicare. Ask your doctor if this test is right for you.


a If you are younger than 50 years old, this test may not be right for you.
b
Mild cognitive impairment (MCI) refers to memory and thinking difficulties beyond normal aging but not significant enough to impact activities of daily living.

 

References

  1. Alzheimer’s Association. Alzheimer’s disease facts and figures. Accessed July 27, 2023. https://www.alz.org/alzheimers-dementia/facts-figures
  2. US Department of Health and Human Services. What is Alzheimer’s disease? Accessed June 6, 2023. https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease
  3. Cummings J, Lee G, Zhong K, et al. Alzheimer’s disease drug development pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1):e12179. doi:10.1002/trc2.12179

Take the first step and talk
to your doctor

We can help you prepare for a
conversation with your doctor about
Alzheimer’s disease or dementia.

Download

Testing for conditions